FDA 483 - Amneal Oncology Private Limited - November 17, 2023

An FDA inspection of Amneal Oncology Private Limited in Hyderabad, India, revealed significant deficiencies in their sterile drug manufacturing operations. The firm failed to adequately investigate out-of-specification results, maintain aseptic processing controls, and validate cleaning processes and test methods. These issues indicate a lack of robust quality systems, potentially impacting the quality and safety of drug products distributed to the U.S. market.